RxDoctor Payments Data

Kevin Theodorou, MD

Internal Medicine · Paradise Valley, AZNPI 1790898880

Payments from drug & device makers

$19,842in general payments, 2019–2025

Across 1,287 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • GSK$1K
  • Pfizer$1K
  • Amgen$1K
  • Lilly USA, LLC$924
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$19,74199%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)185$2,854
AstraZeneca98$2,490
GSK87$1,441
Pfizer111$1,383
Amgen(2 entities)93$1,237
Lilly USA, LLC72$924
Boehringer Ingelheim53$907
Antares Pharma, Inc.92$816
Novo Nordisk42$604
Takeda Pharmaceuticals U.S.A., Inc.57$594
Novartis28$537
Lundbeck LLC41$489
Otsuka America Pharmaceutical, Inc.19$442
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC35$423
Bayer19$413
Nestle Healthcare Nutrition Inc.23$330
Kowa Pharmaceuticals America, Inc.27$307
Johnson & Johnson18$304
Merck14$224
Exact Sciences8$201
Biohaven Pharmaceuticals, Inc.16$200
Biohaven Pharmaceutical Holding Company Ltd.9$186
Amarin Pharma, Inc.11$185
Sumitomo Pharma America, Inc.8$171
Astellas Pharma US Inc8$167
Eisai Inc.8$151
Idorsia Pharmaceuticals US Inc8$145
Sanofi-aventis U.S. LLC9$141
Sunovion Pharmaceuticals Inc.10$136
Currax Pharmaceuticals LLC9$124
Esperion Therapeutics, Inc.7$116
Arbor Pharmaceuticals, Inc.7$102
Abbott5$99
UCB, Inc.4$79
Protega Pharmaceutials Inc2$79
E.r. Squibb & Sons, L.L.C.5$76
Axsome Therapeutics, Inc.3$75
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$69
Vanda Pharmaceuticals Inc.2$58
Gilead3$56
Corcept Therapeutics3$53
Sanofi Pasteur Inc.2$39
Tolmar, Inc.2$38
Verona Pharma, Inc.1$33
Acerus Pharmaceuticals Corporation2$32
Halozyme Inc1$29
Alfasigma USA, Inc.2$29
Nalpropion Pharmaceuticals LLC2$29
Clarus Therapeutics Inc.1$24
Verity Pharmaceuticals Inc.1$24
Lexicon Pharmaceuticals, Inc.1$24
Phathom Pharmaceuticals, Inc.1$22
Nevro Corp.1$19
Eyevance Pharmaceuticals LLC1$19
Hikma Pharmaceuticals USA1$19
Scilex Pharmaceuticals Inc.1$19
Xeris Pharmaceuticals, Inc.1$17
Shire North American Group Inc1$14
Biodelivery Sciences International, Inc.1$14
Jazz Pharmaceuticals Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,842 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$236,464
Medicare patients
320
Services billed
6,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol203$207,254
OzempicSemaglutide123$138,680
EliquisApixaban83$87,672
JardianceEmpagliflozin71$79,419
TrulicityDulaglutide48$74,760
MounjaroTirzepatide52$60,108
XareltoRivaroxaban52$56,553
RybelsusSemaglutide33$52,459
Janumet XrSitagliptin Phos/Metformin Hcl49$52,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$50,393
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$48,810
ProliaDenosumab27$47,495
Xtampza ErOxycodone Myristate36$42,540
VraylarCariprazine Hcl20$40,671
Xigduo XrDapaglifloz Propaned/Metformin24$36,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$2,490$256,064250 claims
Novo NordiskOzempic, Rybelsus$604$191,138156 claims
Lilly USA, LLCTrulicity, Mounjaro$924$134,868100 claims
MerckJanumet Xr, Januvia, Janumet, Belsomra$224$123,038132 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta$1,441$104,219195 claims
Boehringer IngelheimJardiance, Glyxambi$907$101,37290 claims
PfizerEliquis$1,383$87,67283 claims
AmgenProlia, Evenity (2 Syringes)$1,237$77,04739 claims
AbbVieVraylar, Linzess$2,854$74,37752 claims
Johnson & JohnsonXarelto$304$56,55352 claims
Otsuka America Pharmaceutical, Inc.Rexulti$442$32,36321 claims
Astellas Pharma US IncMyrbetriq$167$31,49344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Paradise Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →